In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by the IJGC editorial fellows to discuss the IJGC Special Issue on Rare gynecologic cancers. 

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Sarah E. Ferguson to discuss QoL Assessment on SHAPE Trial.

Dr. Sarah Ferguson is a Gynecologic Oncologist at Princess Margaret Cancer Centre (University Health Network), a Professor and Vice Chair of Research in the Department of Obstetrics and Gynecology at the University of Toronto, and an Associate Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital. Dr. Ferguson is currently the Head of Research for the Department of Obstetrics and Gynecology for Mount Sinai Hospital/University Health Network. Her clinical and research interests include: improving surgical techniques and patient outcomes, survivorship and supportive care as well as hereditary cancer syndromes in gynecology, in particular Lynch syndrome.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Núria Agustí to discuss De-escalation in Gynecologic Oncology. Dr. Agustí specializes in gynecologic oncology at Hospital Clinic of Barcelona. She is currently a PhD researcher at the University of Barcelona and engaged in a postdoctoral fellowship at MD Anderson Cancer Center, USA. She recently completed the IJGC Editorial Fellowship program

In this episode of the IJGC conversations 2025 February Editor's Choice, Editorial Fellow Matteo Marchetti and Thomas Bartl discusses the contents of the 2025 February issue of IJGC. 

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Jose Alejandro Rauh-Hain to discuss LANCE Trial: Results of Feasibility Phase.

Dr. Rauh-Hain is a Gynecologic Oncologist at the University of Texas MD Anderson Cancer Center. Born in Mexico City, he earned his medical degree from Universidad Panamericana and completed a research fellowship at Massachusetts General Hospital, focusing on preeclampsia biomarkers. He trained in Obstetrics and Gynecology at Massachusetts General and Brigham and Women's Hospital, followed by a Gynecologic Oncology fellowship at Harvard Medical School. He also holds an MPH from Harvard and completed a post-doctoral fellowship in Cancer Outcomes Research. His interests include gynecologic cancer surgery, rare tumor management, and research on reducing disparities in cancer care.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Elizabeth (Betty) Suh-Burgmann to discuss Ovarian cancer risk among older patients with stable adnexal masses.

Dr. Elizabeth (Betty) Suh-Burgmann, originally from Boulder, Colorado, earned her Bachelor of Arts from Cornell University and completed her medical degree and residency at the University of California, San Francisco. Following a fellowship at Massachusetts General Hospital/Harvard Medical School, she joined Kaiser Permanente in 2000. She is the Chair of Gynecologic Oncology for Kaiser Permanente Northern California, which provides care to approximately 4.4 million patients. She is the recipient of the 2022 Sidney Garfield Exceptional Contribution Award for her work establishing a standardized ultrasound ovarian cancer risk assessment system within Kaiser. Her research interests include cancer and precancer of the uterus, borderline tumors of the ovary, ultrasound detection of ovarian cancer and cervical cancer screening. 

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Teresa Pan to discuss Preoperative Tumor Size and Final Pathology in Cervical Cancer. Dr. Teresa Pan is a gynonc doctor in the Innsbruck Medical University, Department of Gynecology and Obstetrics and has an interest in research in cervical cancer.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Ramlogan Sowamber to discuss Oral Contraceptive Impact on p53 Signatures. Ramlogan Sowamber is a trainee at the University of British Columbia in the department of Medical Genetics, working with Dr. David Huntsman on understanding the impacts of opportunistic salpingectomy on ovarian cancer risk reduction from a genomic and molecular perspective. He is interested in understanding how genetics influences the mechanisms of cancer progression using genomic and functional approaches and how therapeutic interventions can be applied to various cancer subtypes.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Antonio González-Martín to discuss the results of overall survival in the PRIMA trial. Dr. Antonio González-Martín specializes in the treatment of gynaecological and breast cancer and is the chairman of GEICO (Spanish group for investigation in ovarian and gynaecological cancer). He is also the representative of GEICO in ENGOT (European Network for Gynaecological Oncological Trials), and was the President of this Group for the period 2018-2020. In addition, he is one of the representatives of GEICO in Gynaecologic Cancer InterGroup (GCIG), and has served as chair of the ovarian cancer committee for the period 2014-2020. He is also a member of the board of the Spanish Society of Medical Oncology (SEOM), and a member of GEICAM and SOLTI breast cancer cooperative groups.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Brian Slomovitz to discuss the dMMR population Outcomes from the GOG3053/ENGOT EN11/KEYNOTE B21. Dr. Slomovitz is a Gynecologic Oncologist at Mount Sinai Medical Center in Miami Beach, Florida, and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies.